Daiichi Sankyo
Ifinatamab deruxtecan
Small Cell Lung Cancer
Countdown
297days
Phase 3 readout · Apr 30, 2027
What's at stake
Phase 3 trial results for Ifinatamab deruxtecan in Small Cell Lung Cancer are due Apr 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06203210: Phase 3 trial, sponsor Daiichi Sankyo, drug Ifinatamab deruxtecan. Primary completion date 2027-04-30 (estimated).”